Prostate Specific Antigen - Pipeline Review, H1 2020
Prostate Specific Antigen - Pipeline Review, H1 2020
SUMMARY
Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Prostate-specific antigen (PSA) is a glycoprotein enzyme encoded by the KLK3 gene. PSA is secreted by the epithelial cells of the prostate gland. It is hydrolyzes semenogelin-1 this leads to the liquefaction of the seminal coagulum.
Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) pipeline Target constitutes close to 12 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, IND/CTA Filed and Preclinical stages are 4, 2, 2 and 2 respectively. Similarly, the universities portfolio in Phase II stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology which include indications Prostate Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and Hormone-Sensitive Prostate Cancer.
The latest report Prostate Specific Antigen - Pipeline Review, H1 2020, outlays comprehensive information on the Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Prostate-specific antigen (PSA) is a glycoprotein enzyme encoded by the KLK3 gene. PSA is secreted by the epithelial cells of the prostate gland. It is hydrolyzes semenogelin-1 this leads to the liquefaction of the seminal coagulum.
Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) pipeline Target constitutes close to 12 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, IND/CTA Filed and Preclinical stages are 4, 2, 2 and 2 respectively. Similarly, the universities portfolio in Phase II stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology which include indications Prostate Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and Hormone-Sensitive Prostate Cancer.
The latest report Prostate Specific Antigen - Pipeline Review, H1 2020, outlays comprehensive information on the Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77)
- The report reviews Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) targeted therapeutics and enlists all their major and minor projects
- The report assesses Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Overview
Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Companies Involved in Therapeutics Development
Advaxis Inc
Bavarian Nordic A/S
Etubics Corp
Hookipa Pharma Inc
Inovio Pharmaceuticals Inc
NantKwest Inc
Ohana Vaccine LLC
OncBioMune Pharmaceuticals Inc
OncoQuest Inc
Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Drug Profiles
ADXS-PSA - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy to Target PSA for Prostate Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ETBX-071 + ETBX-061 + ETBX-051 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HB-301 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INO-5150 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INO-5151 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonl Antibody to Inhibit PSA for Prostate Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Pro-V vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ProscaVax - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rilimogene galvacirepvec - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target Brachyury Protein, KLK3 and MUC1 for Castration Resistant Prostate Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target Prostate Specific Antigen for Metastatic Hormone Refractory Prostate Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Dormant Products
Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Discontinued Products
Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Product Development Milestones
Featured News & Press Releases
Feb 13, 2020: Advaxis announces updated survival data in phase 1/2 ADXS-PSA trial at the ASCO Genitourinary Cancers Symposium
Jan 30, 2020: Data on Advaxis’ clinical program ADXS-PSA to be presented at upcoming medical meetings
Oct 07, 2019: Advaxis announces updated prolonged survival data in phase 1/2 ADXS-PSA trial
May 14, 2019: Advaxis announces poster presentation on ADXS-PSA at the Frontiers in Cancer Immunotherapy Conference
May 07, 2019: Advaxis presents on its prostate cancer drug candidate ADXS-PSA at upcoming industry conferences
Apr 01, 2019: ADXS-PSA in combination with Keytruda prolonged survival in metastatic castration-resistant prostate cancer
Mar 19, 2019: Phase 2 trial of OncBioMune’s immunotherapy cancer vaccine ProscaVax for prostate cancer patients in active surveillance now open for enrollment
Mar 11, 2019: Advaxis announces presentation of ADXS-PSA data at upcoming American Association for Cancer Research Annual Meeting
Jan 25, 2019: Data highlighting potential benefits of lm platform presented at 2019 Keystone Symposia Conference on cancer vaccines
Dec 07, 2018: Site visit planned for December 19, 2018 to initiate phase 2 Trial of ProscaVax for early-stage prostate cancer
Nov 08, 2018: OncBioMune phase 2 clinical trial to begin enrollment; company announces other development and corporate milestones
Nov 02, 2018: Advaxis provides update on its Prostate Cancer drug candidate ADXS-PSA
Oct 31, 2018: OncBioMune CEO Dr. Jonathan head speaking at 2018 global summit on genitourinary malignancies
Oct 22, 2018: Inovio Presents Progression Free Survival & PSA Doubling Time Improvements in Prostate Cancer Patients Treated with INO-5150
Oct 16, 2018: OncBioMune Signs Work Order for Phase 2 Clinical Trial of ProscaVax for Late Stage Prostate Cancer
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Overview
Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Companies Involved in Therapeutics Development
Advaxis Inc
Bavarian Nordic A/S
Etubics Corp
Hookipa Pharma Inc
Inovio Pharmaceuticals Inc
NantKwest Inc
Ohana Vaccine LLC
OncBioMune Pharmaceuticals Inc
OncoQuest Inc
Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Drug Profiles
ADXS-PSA - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy to Target PSA for Prostate Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ETBX-071 + ETBX-061 + ETBX-051 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HB-301 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INO-5150 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INO-5151 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonl Antibody to Inhibit PSA for Prostate Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Pro-V vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ProscaVax - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rilimogene galvacirepvec - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target Brachyury Protein, KLK3 and MUC1 for Castration Resistant Prostate Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target Prostate Specific Antigen for Metastatic Hormone Refractory Prostate Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Dormant Products
Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Discontinued Products
Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Product Development Milestones
Featured News & Press Releases
Feb 13, 2020: Advaxis announces updated survival data in phase 1/2 ADXS-PSA trial at the ASCO Genitourinary Cancers Symposium
Jan 30, 2020: Data on Advaxis’ clinical program ADXS-PSA to be presented at upcoming medical meetings
Oct 07, 2019: Advaxis announces updated prolonged survival data in phase 1/2 ADXS-PSA trial
May 14, 2019: Advaxis announces poster presentation on ADXS-PSA at the Frontiers in Cancer Immunotherapy Conference
May 07, 2019: Advaxis presents on its prostate cancer drug candidate ADXS-PSA at upcoming industry conferences
Apr 01, 2019: ADXS-PSA in combination with Keytruda prolonged survival in metastatic castration-resistant prostate cancer
Mar 19, 2019: Phase 2 trial of OncBioMune’s immunotherapy cancer vaccine ProscaVax for prostate cancer patients in active surveillance now open for enrollment
Mar 11, 2019: Advaxis announces presentation of ADXS-PSA data at upcoming American Association for Cancer Research Annual Meeting
Jan 25, 2019: Data highlighting potential benefits of lm platform presented at 2019 Keystone Symposia Conference on cancer vaccines
Dec 07, 2018: Site visit planned for December 19, 2018 to initiate phase 2 Trial of ProscaVax for early-stage prostate cancer
Nov 08, 2018: OncBioMune phase 2 clinical trial to begin enrollment; company announces other development and corporate milestones
Nov 02, 2018: Advaxis provides update on its Prostate Cancer drug candidate ADXS-PSA
Oct 31, 2018: OncBioMune CEO Dr. Jonathan head speaking at 2018 global summit on genitourinary malignancies
Oct 22, 2018: Inovio Presents Progression Free Survival & PSA Doubling Time Improvements in Prostate Cancer Patients Treated with INO-5150
Oct 16, 2018: OncBioMune Signs Work Order for Phase 2 Clinical Trial of ProscaVax for Late Stage Prostate Cancer
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indication, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by Advaxis Inc, H1 2020
Pipeline by Bavarian Nordic A/S, H1 2020
Pipeline by Etubics Corp, H1 2020
Pipeline by Hookipa Pharma Inc, H1 2020
Pipeline by Inovio Pharmaceuticals Inc, H1 2020
Pipeline by NantKwest Inc, H1 2020
Pipeline by Ohana Vaccine LLC, H1 2020
Pipeline by OncBioMune Pharmaceuticals Inc, H1 2020
Pipeline by OncoQuest Inc, H1 2020
Dormant Projects, H1 2020
Discontinued Products, H1 2020
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indication, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by Advaxis Inc, H1 2020
Pipeline by Bavarian Nordic A/S, H1 2020
Pipeline by Etubics Corp, H1 2020
Pipeline by Hookipa Pharma Inc, H1 2020
Pipeline by Inovio Pharmaceuticals Inc, H1 2020
Pipeline by NantKwest Inc, H1 2020
Pipeline by Ohana Vaccine LLC, H1 2020
Pipeline by OncBioMune Pharmaceuticals Inc, H1 2020
Pipeline by OncoQuest Inc, H1 2020
Dormant Projects, H1 2020
Discontinued Products, H1 2020
LIST OF FIGURES
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020
COMPANIES MENTIONED
Advaxis Inc
Bavarian Nordic A/S
Etubics Corp
Hookipa Pharma Inc
Inovio Pharmaceuticals Inc
NantKwest Inc
Ohana Vaccine LLC
OncBioMune Pharmaceuticals Inc
OncoQuest Inc
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020
COMPANIES MENTIONED
Advaxis Inc
Bavarian Nordic A/S
Etubics Corp
Hookipa Pharma Inc
Inovio Pharmaceuticals Inc
NantKwest Inc
Ohana Vaccine LLC
OncBioMune Pharmaceuticals Inc
OncoQuest Inc
